Like in the present study, a reduced rate of TP53 mutations in carriers of the SNP309G allele has been reported for non-small cell lung cancer [55], hepatocellular carcinoma [35], and bladder cancer [56]. Here, TP53 is linked to urinary bladder carcinoma.